+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia



Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia



Clinical Neuropharmacology 29(1): 28-33



Background: Approximately 40% to 70% of neuroleptic-resistant schizophrenic patients are nonresponders to clozapine. Several clozapine augmentation strategies have come into clinical practice although often without evidence-based support.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011791790

Download citation: RISBibTeXText

PMID: 16518132

DOI: 10.1097/00002826-200601000-00009


Related references

Augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment. Turk Psikiyatri Dergisi 25(3): 201-211, 2014

Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opinion on PharmacoTherapy 15(16): 2329-2345, 2014

Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: A comparative meta-analysis. Heliyon 3(11): E00429, 2017

Augmentation strategies in clozapine-resistant schizophrenia. Cns Drugs 19(10): 843-872, 2005

Augmentation strategies in the treatment of major depressive disorder. Examining the evidence on augmentation with atypical antipsychotics. Cns Spectrums 12(12 Suppl 22): 10-12, 2007

Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry Research 188(3): 315-319, 2011

Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. Australian and new Zealand Journal of Psychiatry 52(8): 751-767, 2018

Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophrenia Bulletin 38(5): 1003-1011, 2012

Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Therapeutic Advances in Drug Safety 9(5): 237-256, 2018

Mega-review of meta-analyses investigating the short-term efficacy of pharmacologic augmentation strategies of antipsychotics in patients with schizophrenia. European Psychiatry 33: S550-S551, 2016

Treatment-resistant schizophrenia: Neutropenia with olanzapine and clozapine, and stabilization with two depot antipsychotics. Vertex 28(132): 141-144, 2017

Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia. American Journal of Psychiatry 160(6): 1133-1138, 2003

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland. Bmc Psychiatry 16(1): 441, 2016

Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry 209(5): 385-392, 2016

Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia. Comprehensive Psychiatry 40(2): 148-150, March-April, 1999